Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy.
Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy.
复制标题
骨髓采集产品的肿瘤细胞污染：接受高剂量化疗的晚期乳腺癌患者队列的临床后果。
DOI：
--
复制
发表时间：
1996
期刊：
影响因子：
--
通讯作者：
S. Williams
中科院分区：
文献类型：
--
作者：
B. Brockstein;A. A. Ross;T. Moss;D. Kahn;K. Hollingsworth;S. Williams
接受大剂量化疗(HDC)和自体干细胞拯救(ASCR)的患者，如果他们的干细胞产品被肿瘤污染，可能会无意中注入肿瘤细胞。我们用免疫细胞化学(ICC)方法分析了31例组织学阴性的晚期乳腺癌患者在HDC前采集骨髓标本。所有31名患者都接受了三种连续HDC方案中的一种治疗，并接受了骨髓或骨髓和外周干细胞(PSC)作为ASCR。在26名可评估的患者中，有6名在他们的骨髓收获中发现了ICC可检测到的污染肿瘤细胞。与那些没有ICC可检测到肿瘤细胞的患者相比，这6名患者的总生存期有下降的趋势(中位数17个月对25个月以上，p=0.11，对那些完全缓解的患者进行对数等级检验，CR，来自HDC)。当分析新的发病部位和以前的发病部位时，ICC阳性组和ICC阴性组的复发部位没有显著差异。因此，我们对一小部分患者的回顾性分析表明，接受HDC治疗的乳腺癌患者输注肿瘤细胞可能会带来不良的预后。然而，复发模式表明，无论是在新的部位还是在以前的疾病部位，都是失败的。还需要在扩大的患者群体中进行更多的研究，以进一步探索肿瘤细胞输注在ASCR中的作用以及肿瘤细胞切除手术可能带来的临床好处。
Patients undergoing high-dose chemotherapy (HDC) with autologous stem cell rescue (ASCR) may have tumor cells inadvertently infused if their stem cell product is tumor contaminated. We used an immunocytochemical (ICC) method to analyze 31 histologically negative bone marrow (BM) specimens taken from women with advanced-stage breast cancer at the time of BM harvest before HDC. All 31 patients were treated on one of three consecutive HDC protocols and received BM or BM and peripheral stem cells (PSC) as ASCR. Six of 26 evaluable patients had ICC-detectable contaminating tumor cells in their BM harvests. These 6 patients had a trend toward decreased overall survival compared with those patients without ICC-detectable tumor cells (17 months median versus 25+ months, p = 0.11, log rank test for those patients achieving complete response, CR, from HDC). The sites of relapse in the ICC-positive and ICC-negative groups were not notably different when analyzed for new sites versus previous sites of disease. Therefore, our retrospective analysis of a small cohort of patients suggests that the infusion of tumor cells in breast cancer patients undergoing HDC may confer a poor prognosis. Relapse patterns however suggest failure both in new sites and in sites of previous disease. Additional studies in expanded patient populations are needed to explore further the role of tumor cell infusion in ASCR and the possible clinical benefits of tumor cell removal procedures.
登录
查看更多内容
循环神经母细胞瘤细胞污染外周血干细胞收获物。
影响因子：
20.3
作者：
Moss,TJ;Sanders,DG;Lasky,LC;Bostrom,B
通讯作者：
Bostrom,B
通过 bcl-2 易位的聚合酶链反应扩增检测净化的骨髓和外周血单核细胞中的肿瘤细胞。
DOI：
10.1200/jco.1994.12.5.1021
发表时间：
1994
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Negrin,RS;Pesando,J
通讯作者：
Pesando,J
使用单克隆抗体和免疫磁珠去除，可以清除具有 bcl-2 易位的非霍奇金淋巴瘤患者的骨髓中的聚合酶链反应可检测的淋巴瘤细胞。
影响因子：
20.3
作者：
Gribben,JG;Saporito,L;Barber,M;Blake,KW;Edwards,RM;Griffin,JD;Freedman,AS;Nadler,LM
通讯作者：
Nadler,LM
所有具有聚合酶链式反应可放大 bcl-2 断点的晚期非霍奇金淋巴瘤在评估时和治疗后均具有含有 bcl-2 重排的残留细胞。
影响因子：
20.3
作者：
Gribben,JG;Freedman,As;Woo,SD;Blake,K;Shu,RS;Freeman,G;Longtine,JA;Pinkus,GS;Nadler,LM
通讯作者：
Nadler,LM